AbbVie Inc.
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?
ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.
EPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma
AbbVie (NYSE: ABBV) announced today that Health Canada has issued a Notice of Compliance for EPKINLY® (epcoritamab) with a new follicular lymphoma (FL) indication. EPKINLY®, in combination with lenalidomide and rituximab, is indicated for the treatment of adult patients with relapsed or refractory Grade 1, 2, or 3a FL who have received at least one prior line of systemic therapy.6
Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade
It would be hard for investors to replicate the company's return over the past decade.
Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO
AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U.S. IPO on September 21 after raising money from NVIDIA Corporation (NASDAQ:NVDA) and Qatar Investment Authority, and the same day announced a multi-year research collaboration with AbbVie Inc. (NYSE:ABBV). Iambic will use its AI platform to […]
AbbVie: Revenue Pressure And Weakening Earnings Support A 'Sell'
AbbVie is rated a "Sell" with a $191 target, implying 27.7% downside from the current $264 price. Click here to read more about the ABBV stock.
What Is AbbVie No Longer Telling You?
AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.
2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie
Johnson & Johnson vs. AbbVie valuation: JNJâs P/E & PEGY premium looks justified by a strong balance sheet, buybacks, and more. Read the full analysis here.
AbbVie (ABBV) Won EU Approval For RINVOQ In Pediatric Arthritis
AbbVie (NYSE:ABBV) received European Commission approval for RINVOQ in polyarticular juvenile idiopathic arthritis for patients as young as two. Allergan Aesthetics launched AA Signature SKIN360 in the U.S., offering a multimodal digital platform for medical aesthetics consultations. AbbVie entered AI-focused collaborations with Iambic and the AISB Bind project to use advanced models in drug discovery and molecular binding prediction. The RINVOQ pediatric extension, AA Signature SKIN360...
AbbVie (ABBV) Wins EU Approval for Rinvoq in Children. Why a Small Indication Still Matters
AbbVie Inc. (NYSE:ABBV) said on September 22 that the European Commission has approved Rinvoq for children aged two and older with active polyarticular juvenile idiopathic arthritis. The approval covers patients who did not respond to, or could not tolerate, standard disease-modifying drugs. It is the eleventh indication Rinvoq holds in Europe. The Commission also cleared […]
Congressional Trades in $ABBV
Insider Trades (Form 4)
RAPP EDWARD J
Hart Brett J
WADDELL FREDERICK H
Roberts Rebecca B
Quaggin Susan E
MEYER MELODY B
FALK THOMAS J
FREYMAN THOMAS C
Key People
Davis Jennifer L
Director
WADDELL FREDERICK H
Director
Hart Brett J
Director
SALEKI-GERHARDT AZITA
EVP, CHIEF OPERATIONS OFFICER
Thakkar Roopal
EVP, R&D and CSO
Purdue David Ryan
SVP, Controller
Michael Robert A
CHAIRMAN OF THE BOARD AND CEO
Crum Demetris D
EVP, CHIEF HR OFFICER
FALK THOMAS J
Director
RAPP EDWARD J
Director
TILTON GLENN F
Director
Reents Scott T
EVP, CHIEF FINANCIAL OFFICER
Michael Robert A
CHIEF EXECUTIVE OFFICER
Buckbee Kevin K
SVP, CONTROLLER
Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
GONZALEZ RICHARD A
Director
Quaggin Susan E
Director
GONZALEZ RICHARD A
EXECUTIVE CHAIRMAN OF BOARD
BURNSIDE WILLIAM H L
Director
Political Giving
$402,500 given to 65 candidates across 165 disclosed contributions (FEC Schedule A).
Darin McKay LaHood
Bradley S. Schneider
Earl Leroy Carter
Adrian Smith
Nanette Barragan
Scott H. Peters
Jennifer McClellan
Terri A. Sewell
Linda T. Sanchez
Ashley Moody
Guy Mr Reschenthaler
Jake Auchincloss
Lori Trahan
Dan Sullivan
Susan M. Collins
Suzan K. DelBene
Thomas H. Kean
Shelley Moore Capito
James Comer
Kevin Hern
+ 45 more recipients not shown.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro